T cell modifying compounds and uses thereof
US-9597357-B2 · Mar 21, 2017 · US
US12344572B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12344572-B2 |
| Application number | US-202016920556-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 3, 2020 |
| Priority date | Jul 3, 2019 |
| Publication date | Jul 1, 2025 |
| Grant date | Jul 1, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
Opening claim text (preview).
What is claimed is: 1. A compound of Formula (V) wherein R 21 , R 23 , and R 24 are independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxyalkyl, C 5-10 aryl, 5- to 10-membered heteroaryl, or C 3-6 cycloalkyl; n is an integer from 1 to 20; m is 6, 7, 8, 9, or 10; p is 1, 2, 3, or 4; q is 1, 2, 3, 4, or 5; and r is 1, 2, 3, 4, 5, or 6. 2. The compound of claim 1 , wherein R 21 , R 23 , and R 24 are hydrogen. 3. The compound of claim 1 , wherein n is 16, 17, 18, 19, or 20. 4. The compound of claim 3 , wherein: q is 4; p is 1; and r is 1. 5. The compound of claim 3 , wherein m is 8. 6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient. 7. A lipid aggregate comprising a compound of claim 1 . 8. The lipid aggregate of claim 7 , wherein the lipid aggregate does not comprise one or more additional lipids or polymers. 9. The lipid aggregate of claim 7 further comprising a nucleic acid, selected from a DNA molecule or an RNA molecule. 10. The compound of claim 1 , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 11. The compound of claim 1 , wherein n is 4.
Dispersions; Emulsions · CPC title
Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title
Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine · CPC title
Compounds having three or more nucleosides or nucleotides · CPC title
comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.